Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/pbc.24182 http://scihub22266oqcxt.onion/10.1002/pbc.24182 C4587903!4587903 !22532399     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=22532399 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Pediatr+Blood+Cancer 2012 ; 59 (5 ): 925-7 Nephropedia Template TP {{tp|p=22532399 |t=2012. Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia |pdf=|usr=}}{{22532399 }} gab.com Text Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia JO: Pediatr Blood Cancer http://www.kidney.de/pget.php?&tw=1&pmid=22532399 #FOAvip Although L-asparaginase (ASP) is associated with several toxicities, its myelosuppressive effect has not been well characterized. On DFCI ALL Consortium Protocol 05-01 for children with newly diagnosed acute lymphoblastic leukemia, the Consolidation phase and the initial portion of the Continuation phase were identical for standard risk patients, except ASP was given only during Consolidation. Comparing the two treatment phases revealed that low blood counts during Consolidation with ASP resulted in more dosage reductions of 6-mercaptopurine and methotrexate. The myelosuppressive effect of ASP should be considered when designing treatment regimens to avoid excessive toxicity and dose reductions of other critical chemotherapy agents. Twit Text FOAVip Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia ????Pediatr Blood Cancer http://www.kidney.de/pget.php?&tw=1&pmid=22532399 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22532399 #FOAvip English Wikipedia <ref>{{Cite pmid|22532399 }}</ref> Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia #MMPMID22532399 Merryman R ; Stevenson KE ; Gostic WJ 2nd ; Neuberg D ; O'Brien J ; Sallan SE ; Silverman LB Pediatr Blood Cancer 2012[Nov]; 59 (5 ): 925-7 PMID22532399 show ga Although L-asparaginase (ASP) is associated with several toxicities, its myelosuppressive effect has not been well characterized. On DFCI ALL Consortium Protocol 05-01 for children with newly diagnosed acute lymphoblastic leukemia, the Consolidation phase and the initial portion of the Continuation phase were identical for standard risk patients, except ASP was given only during Consolidation. Comparing the two treatment phases revealed that low blood counts during Consolidation with ASP resulted in more dosage reductions of 6-mercaptopurine and methotrexate. The myelosuppressive effect of ASP should be considered when designing treatment regimens to avoid excessive toxicity and dose reductions of other critical chemotherapy agents. |Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects [MESH] |Asparaginase/*administration & dosage/adverse effects [MESH] |Child [MESH] |Child, Preschool [MESH] |Female [MESH] |Humans [MESH] |Infant [MESH] |Mercaptopurine/administration & dosage/adverse effects [MESH] |Methotrexate/administration & dosage/adverse effects [MESH]Asparaginase-associated myelosuppression and effects on dosing of othe(epmc).pdf DeepDyve Pubget Overpricing